AN2 Therapeutics stockholders elect three Class III directors and ratify PwC as auditor

AN2 Therapeutics, Inc.

Eric Easom, Stephanie Wong, and Joseph Zakrzewski elected as Class III directors for term expiring 2028.
Easom received 13,983,213 votes for; Wong 10,584,641; Zakrzewski 10,928,200; each had 3,403,334 broker non-votes.
Ratification of PricewaterhouseCoopers LLP as independent auditor passed with 23,736,942 votes for, 47,413 against, 144,085 abstentions.
Approximately 79.50% of outstanding shares (23,928,440) represented at the meeting, constituting a quorum.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.